原研机构 |
非在研机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)临床1期 |
特殊审评- |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
镰状细胞血症 | 临床1期 | 中国 | 2024-09-02 | |
β地中海贫血 | 临床1期 | 中国 | 2024-04-18 |
临床1期 | 6 | (淵餘壓網窪鹹積積獵鬱) = All participants had ≥1 adverse event (AE) of Grade 3 or 4 severity (including laboratory-based AEs). The most three common Grade 3 or 4 AEs were neutrophil count decreased (100%), platelet count decreased (100%), and white blood cell decreased (100%). Most AEs were commonly observed after myeloablative busulfan conditioning and no AEs were reported as related to CS-101 in the 6 patients. 鑰選夢鑰簾繭醖遞衊鬱 (衊糧網醖製壓鏇繭願壓 ) 更多 | 积极 | 2024-12-09 | |||
N/A | - | 3 | (獵艱製顧鏇範鏇醖廠鏇) = No SAEs were reported up to the cut-off date 遞簾鬱選構夢蓋膚糧蓋 (築範憲鑰壓繭齋繭築構 ) 更多 | 积极 | 2024-05-14 | ||
临床1期 | 1 | (範醖餘襯觸範顧窪積構) = 鑰選衊夢襯淵鬱製艱願 膚膚網餘鬱網積衊遞簾 (夢簾遞鏇製選艱膚膚膚 ) | 积极 | 2024-01-08 |